Postprandial glycemia and cardiovascular disease in diabetes mellitus

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 2, 2007, Pages 212-221

  Wajchenberg, Bernardo Léo ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cardiovascular disease; Diabetes mellitus; Glucose intolerance; Impaired fasting glucose; Postprandial glycemia

Indexed keywords

EID: 34248571657     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302007000200010     Document Type: Review

References (50)

1. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001;24:775-8.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 1998;352:837-53.
3. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 Diabetes. Diabetes Care 1997;20:1822-6.
4. El-Kebbi JM, Ziemer DC, Cook CB, Gallina DL, Barnes CS, Phillips LS. Utility of casual postprandial glucose levels in type 2 diabetes management. Diabetes Care 2004;27:335-9.
5. Rohlfing CL, Wiemeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-8.
6. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
7. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 2000;43:148-55.
8. Dahl-Jorgensen K, Larsen JR, Hanssen KF. Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment. Diabetologia 2005;48:1445-53.
9. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb 1992;12:647-56.
10. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999;48:937-42.
11. Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006;12(suppl 1):42-6.
12. Bell DS. Importance of postprandial glucose control. South Med J 2001;94:804-9.
13. Heine RJ, Dekker JM. Beyond postprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002;45:461-75.
14. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
15. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality? Diabetes Care 1999;22;659-60.
16. Khaw K-T, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of Hemoglobin A1c and cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med 2004;141:413-20.
17. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236-9.
18. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006;29:1130-9.
19. Meyer C, Pimenta W, Woerle HJ, Haeften TV, Szose E, Mitrakou A, et al. Different mechanisms for Impaired fasting Glucose and Impaired postprandial glucose tolerance in humans. Diabetes Care 2006;29:1909-14.
20. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, et al. Role of reduced suppression of glucose production and diminished early insulin release in Impaired glucose tolerance. N Engl J Med 1992;326:22-9.
21. Ceriello A. Postprandial hyperglycemia and diabetes complications. Is it time to treat? Diabetes 2005;54:1-7.
22. Teno S, Uto Y, Nagashima H, Endoh Y, Iwamoto Y, Omori Y, et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-6.
23. Iovine C, Vaccaro O, Gentile A, Romano G, Pisanti F, Riccardi G, et al. Post-prandial triglyceride profile in a population-based sample of Type 2 diabetic patients. Diabetologia 2004;47:19-22.
24. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24:816-23.
25. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
26. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl Lg, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1999;276:882-8.
27. Wolever TMS, Chiasson JL, Csima A, Hunt JA, Palmason C, Ross SA, et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed meal versus 75 g oral glucose. Diabetes Care 1998;21:336-40.
28. de Vegt F, Dekker JM, Ruhè HG, Stehouwer CDA, Nijpels GBLM, Heine RJ. Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-31.
29. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 1997;36:689-92.
30. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry study. Diabetes Care 1997;20:163-9.
31. The DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-21.
32. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-h diagnostic criteria. Arch Intern Med 2001;161:397-404.
33. Balkau B, Shipley M, Jarrett RJ, Pyörälla K, Pyörälla M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-7.
34. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al; the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, a 11-year follow-up. Diabetologia 1996;39:1577-83.
35. Hanenfeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999;144:229-35.
36. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005;54:1615-25.
37. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-66.
38. Vinik A. The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications. Expert Opin Investig Drugs 2005;14:1547-59.
39. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998;22(suppl. 1):S5-S19.
40. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes: the STOP-NIDDM randomized trial. Lancet 2002;359:2072-7.
41. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94.
42. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073-8.
43. Esposito K, Giugliano D, Nappo F, Marfella R; for the Campanian Post-prandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-9.
44. Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care 2002;25:1271-6.
45. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M-C, Avogaro A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99-105.
46. Baggio LL, Drucker DJ. Incretin hormones in the treatment of type 2 diabetes: Therapeutic applications of DPP-IV inhibitors. Medscape Diabetes Endocrinol 2006;8:1-5.
47. Wajcberg E, Triplitt C, Sriwijitkamol A, De Fronzo R, Cerosimo E. Contribution of glucagon suppression to improved postprandial hyperglycemia induced by exenatide in patients with TT2MM [Abstract 118-OR]. Diabetes 2006;55(suppl 1);A28.
48. Mari A, Halseth A, Nanayakkara N, Nielsen L, DeFronzo R, Ferrannini E. Mathematical modeling shows exenatide improved postprandial β-cell function in patients with type 2 diabetes treated with metformin or metformin and sulfonylurea [Abstract 482-P]. Diabetes 2005;54(suppl. 1);A119.
49. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Characterization of beta-cell function improvement by liraglutide: modeling analysis of 24-h tests [Abstract 522 -P]. Diabetes 2006;55(suppl. 1):A124.
50. Drucker DJ. DPP-4 inhibitors in the management of type 2 diabetes. Mechanisms in Medicine Inc., 2006. p. 59.